Mounjaro vs Ozempic vs Wegovy in Malaysia: Which GLP-1 Drug Is Right for You?

With more GLP-1 weight loss medications becoming available globally, many patients in Malaysia ask: what is the difference between Ozempic, Wegovy, Saxenda, and Mounjaro, and which should I be taking? The answer depends on your health profile, weight loss goals, and what is clinically available in Malaysia. This guide breaks down each medication clearly.

What Are These Medications?

Semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic was originally approved for type 2 diabetes management and is administered once weekly at doses up to 2mg. It produces meaningful weight loss as a secondary benefit. Wegovy contains the same molecule at a higher maximum dose of 2.4mg per week, specifically approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Saxenda (liraglutide) is an older GLP-1 receptor agonist that requires daily injection rather than weekly. It targets the same biological pathway but has a shorter half-life, which necessitates more frequent dosing. Its clinical efficacy for weight loss is lower than semaglutide-based products, though it was the first GLP-1 medication approved specifically for obesity treatment in many markets.

Mounjaro (tirzepatide) represents a newer class of medication, a dual agonist acting on both GIP (glucose-dependent insulinotropic polypeptide) receptors and GLP-1 receptors simultaneously. This dual mechanism appears to produce superior weight loss outcomes compared to GLP-1-only medications in head-to-head clinical trials. Tirzepatide is administered once weekly and was originally developed for type 2 diabetes management.

How Much Weight Can You Expect to Lose?

Clinical trial data provides the clearest picture of comparative efficacy. The STEP 1 trial demonstrated that semaglutide 2.4mg (Wegovy dose) produced an average weight loss of approximately 15.2% of body weight over 68 weeks in adults with obesity. Ozempic at standard diabetes doses typically produces 10-12% weight loss, with some patients achieving up to 15% at the 2mg dose.

The SURMOUNT-1 trial evaluated tirzepatide (Mounjaro) in adults with obesity and found average weight loss of 15.0%, 19.5%, and 20.9% for the 5mg, 10mg, and 15mg doses respectively over 72 weeks. This represented a significant improvement over semaglutide's benchmark results and established tirzepatide as the most effective approved weight loss medication at the time of the trial.

Saxenda (liraglutide) at its maximum approved dose of 3mg daily produces average weight loss of approximately 7-8% in clinical trials, making it the least potent of the four medications for weight management. However, individual responses vary considerably. Some patients on any GLP-1 medication lose significantly more than the trial average, while others respond less strongly. Adherence, diet, exercise, and individual metabolic factors all influence outcomes.

What Is Available in Malaysia?

Seimbang doctors prescribe GLP-1-class therapy based on semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (Mounjaro). Saxenda (liraglutide) is also prescribed by some providers in Malaysia, though its lower efficacy makes it a less common first-line choice.

Which medication is appropriate for you depends on your medical eligibility, how you tolerate treatment, and the supply available at the time — brand availability in Malaysia can change. Your Seimbang doctor confirms at your consultation what can currently be prescribed.

Head-to-Head Comparison

The table below provides a quick reference comparison of the four GLP-1 class medications based on clinical trial data. Weight loss figures represent average outcomes from pivotal trials at the highest approved doses.

It is important to note that these figures represent population averages from controlled clinical trial conditions. Real-world outcomes vary based on individual adherence, lifestyle factors, and biological response. Your treating physician will set realistic expectations based on your specific health profile.

Side Effects: Are They the Same?

All four medications share a similar gastrointestinal side effect profile, as they work through overlapping mechanisms in the gut and brain. The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation, and reduced appetite, particularly during the dose escalation phase when your body is adjusting to the medication. These effects typically diminish significantly after the first 4-8 weeks of treatment.

Mounjaro (tirzepatide) may produce slightly more pronounced nausea in some patients during initial dose escalation, likely due to its additional GIP receptor activity. However, this tends to resolve as tolerance develops. Saxenda's daily dosing schedule means some patients experience more persistent low-grade nausea compared to weekly injections. All GLP-1 class medications carry a theoretical risk of pancreatitis and should be used with caution in patients with relevant history.

How Seimbang Approaches Medication Choice

Every patient who starts GLP-1 treatment at Seimbang undergoes a thorough medical intake assessment that captures their weight history, metabolic markers, comorbidities, lifestyle factors, and treatment goals. This information guides the medication choice, starting dose, and titration schedule, ensuring each patient receives a clinically appropriate treatment plan rather than a one-size-fits-all approach.

Seimbang doctors prescribe semaglutide- or tirzepatide-based therapy, matched to each patient's health profile, goals and tolerability rather than a one-size-fits-all choice. As the evidence base and available options develop, doctors incorporate them into their prescribing practice.